Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients
Objective: The aim of this prospective cohort study is to analyse the humoral and cellular vaccine responses in paediatric heart transplant recipients (HTR, n = 12), and compare it with the response in healthy controls (HC, n = 14). All participants were 5–18 years old and vaccinated with mRNA vacci...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024176153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850029036988792832 |
|---|---|
| author | Amanda Bermejo-Gómez Laura Tarancon-Diez Beatriz Lazaro-Martin Begoña Santiago-Garcia Nuria Gil Villanueva Roberto Alonso Mª Ángeles Muñoz-Fernández Manuela Camino López Alicia Hernanz-Lobo María Luisa Navarro Gómez |
| author_facet | Amanda Bermejo-Gómez Laura Tarancon-Diez Beatriz Lazaro-Martin Begoña Santiago-Garcia Nuria Gil Villanueva Roberto Alonso Mª Ángeles Muñoz-Fernández Manuela Camino López Alicia Hernanz-Lobo María Luisa Navarro Gómez |
| author_sort | Amanda Bermejo-Gómez |
| collection | DOAJ |
| description | Objective: The aim of this prospective cohort study is to analyse the humoral and cellular vaccine responses in paediatric heart transplant recipients (HTR, n = 12), and compare it with the response in healthy controls (HC, n = 14). All participants were 5–18 years old and vaccinated with mRNA vaccine against SARS-CoV-2 between December 2021 and May 2022. Methods: The humoral response was measured by quantifying antibody titers against SARS-CoV-2 spike protein (anti-S). The T-lymphocyte phenotype and SARS-CoV2-specific CD4+ and CD8+ T-cell response was studied by multiparametric flow cytometry through peripheral blood mononuclear cells by the quantification of degranulation markers (CD107a) and intracellular cytokines (IFN-γ, TNF-α and IL-2) after in vitro stimulation with SARS-CoV-2 peptides from structural proteins (S, M, N, E) and non-structural viral proteins. Results: After vaccination, humoral response was found in all HTR, although they showed lower levels of anti-S IgG compared to HC (p = 0.003). However, in terms of cellular response, no significant differences were obtained in the prevalence of responders and magnitude of responses between groups. In addition, anti-S IgG levels directly correlated with a higher SARS-CoV-2 specific T-cell response (rho = 0.43; p = 0.027 and rho = 0.45; p = 0.02 for IFN-γ+ and TNF-α+ production of CD8+ T-cells, respectively). Activated T-cell phenotype in HTR was associated with a lower humoral response to SARS-CoV-2 vaccine. Conclusion: HTR had humoral response after vaccination, although they showed lower levels of specific anti-S antibodies compared to HC. There were no significant differences in the SARS-CoV2-specific cellular response between the two groups. Obtaining satisfactory data on this type of response could potentially challenge the current vaccine guideline recommendations. |
| format | Article |
| id | doaj-art-aa8e7ba2341a4143aaa34cd913a36b84 |
| institution | DOAJ |
| issn | 2405-8440 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-aa8e7ba2341a4143aaa34cd913a36b842025-08-20T02:59:38ZengElsevierHeliyon2405-84402025-01-01111e4158410.1016/j.heliyon.2024.e41584Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipientsAmanda Bermejo-Gómez0Laura Tarancon-Diez1Beatriz Lazaro-Martin2Begoña Santiago-Garcia3Nuria Gil Villanueva4Roberto Alonso5Mª Ángeles Muñoz-Fernández6Manuela Camino López7Alicia Hernanz-Lobo8María Luisa Navarro Gómez9Pediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain; Gregorio Marañón Research Health Institute (IiSGM), Madrid, SpainPediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain; Gregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Biomedical Research Centre Network for Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, SpainPediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain; Gregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Biomedical Research Centre Network for Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, SpainPediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain; Gregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Biomedical Research Centre Network for Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, SpainPediatric Cardiology Department, Gregorio Marañón Hospital, Madrid, SpainGregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Gregorio Marañón University Hospital, Madrid, Spain; Complutense University, Madrid, SpainGregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Molecular Immunology Laboratory, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III (ISCIII), Madrid, SpainPediatric Cardiology Department, Gregorio Marañón Hospital, Madrid, SpainPediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain; Gregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Biomedical Research Centre Network for Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, SpainPediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain; Gregorio Marañón Research Health Institute (IiSGM), Madrid, Spain; Biomedical Research Centre Network for Infectious Diseases (CIBERINFEC), Carlos III Health Institute, Madrid, Spain; Complutense University, Madrid, Spain; Corresponding author. Pediatric Infectious Diseases Unit, Department of Pediatrics, Gregorio Marañón University Hospital, Madrid, Spain.Objective: The aim of this prospective cohort study is to analyse the humoral and cellular vaccine responses in paediatric heart transplant recipients (HTR, n = 12), and compare it with the response in healthy controls (HC, n = 14). All participants were 5–18 years old and vaccinated with mRNA vaccine against SARS-CoV-2 between December 2021 and May 2022. Methods: The humoral response was measured by quantifying antibody titers against SARS-CoV-2 spike protein (anti-S). The T-lymphocyte phenotype and SARS-CoV2-specific CD4+ and CD8+ T-cell response was studied by multiparametric flow cytometry through peripheral blood mononuclear cells by the quantification of degranulation markers (CD107a) and intracellular cytokines (IFN-γ, TNF-α and IL-2) after in vitro stimulation with SARS-CoV-2 peptides from structural proteins (S, M, N, E) and non-structural viral proteins. Results: After vaccination, humoral response was found in all HTR, although they showed lower levels of anti-S IgG compared to HC (p = 0.003). However, in terms of cellular response, no significant differences were obtained in the prevalence of responders and magnitude of responses between groups. In addition, anti-S IgG levels directly correlated with a higher SARS-CoV-2 specific T-cell response (rho = 0.43; p = 0.027 and rho = 0.45; p = 0.02 for IFN-γ+ and TNF-α+ production of CD8+ T-cells, respectively). Activated T-cell phenotype in HTR was associated with a lower humoral response to SARS-CoV-2 vaccine. Conclusion: HTR had humoral response after vaccination, although they showed lower levels of specific anti-S antibodies compared to HC. There were no significant differences in the SARS-CoV2-specific cellular response between the two groups. Obtaining satisfactory data on this type of response could potentially challenge the current vaccine guideline recommendations.http://www.sciencedirect.com/science/article/pii/S2405844024176153SARS-CoV-2VaccinesPaediatricImmunocompromisedHeart transplant recipientsCOVID-19 |
| spellingShingle | Amanda Bermejo-Gómez Laura Tarancon-Diez Beatriz Lazaro-Martin Begoña Santiago-Garcia Nuria Gil Villanueva Roberto Alonso Mª Ángeles Muñoz-Fernández Manuela Camino López Alicia Hernanz-Lobo María Luisa Navarro Gómez Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients Heliyon SARS-CoV-2 Vaccines Paediatric Immunocompromised Heart transplant recipients COVID-19 |
| title | Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients |
| title_full | Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients |
| title_fullStr | Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients |
| title_full_unstemmed | Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients |
| title_short | Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients |
| title_sort | humoral and cellular response to sars cov 2 mrna vaccine in paediatric heart transplant recipients |
| topic | SARS-CoV-2 Vaccines Paediatric Immunocompromised Heart transplant recipients COVID-19 |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024176153 |
| work_keys_str_mv | AT amandabermejogomez humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT lauratarancondiez humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT beatrizlazaromartin humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT begonasantiagogarcia humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT nuriagilvillanueva humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT robertoalonso humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT maangelesmunozfernandez humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT manuelacaminolopez humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT aliciahernanzlobo humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients AT marialuisanavarrogomez humoralandcellularresponsetosarscov2mrnavaccineinpaediatrichearttransplantrecipients |